Related Experiment Video

Updated: Jul 16, 2026

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
07:46

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation

Published on: April 3, 2017

Impaired mononuclear cell immune function in extreme obesity is corrected by weight loss

Luigi Fontana1, J Christopher Eagon, Marco Colonna

  • 1Division of Geriatrics and Nutritional Sciences, Washington University School of Medicine, St. Louis, Missouri 63110, USA. lfontana@im.wustl.edu

Rejuvenation Research
|March 24, 2007
PubMed
Abstract

Insights

Extreme obesity significantly suppresses immune cell production of key signaling molecules. Weight loss reverses this suppression, restoring normal immune function and potentially reducing infection risk.

Area of Science:

  • Immunology
  • Metabolic Disorders
  • Infectious Disease

Background:

  • Obesity is linked to increased infection susceptibility and severity.
  • Mechanisms underlying obesity-related infection risk remain unclear.
  • Immune cell chemokine and cytokine production are crucial for fighting pathogens.

Purpose of the Study:

  • To investigate the impact of extreme obesity and subsequent weight loss on immune cell function.
  • To assess changes in macrophage chemoattractant protein-1 (MCP-1) and interferon-gamma (IFNgamma) production by peripheral blood mononuclear cells (PBMCs).

Main Methods:

  • Compared immune cell function in extremely obese subjects versus lean controls.
  • Measured MCP-1 and IFNgamma production by PBMCs stimulated with lipopolysaccharide (LPS) and phorbol 12-myristate 13-acetate plus ionomycin (PMA + I).
  • Evaluated changes in obese subjects one year after gastric bypass surgery.

Main Results:

  • Obese subjects exhibited significantly lower LPS-stimulated MCP-1 and PMA+I-stimulated IFNgamma production compared to lean individuals.
  • Gastric bypass surgery led to substantial weight loss (30.3%) in obese subjects.
  • Weight loss normalized MCP-1 and IFNgamma production by PBMCs in previously obese subjects.

Conclusions:

  • Immune cell production of IFNgamma and MCP-1 is markedly suppressed in extreme obesity.
  • Weight loss effectively restores normal immune cell function in producing these critical molecules.
  • Findings highlight a significant beneficial effect of weight loss on immune function, potentially explaining reduced infection risk in leaner individuals.

More Related Videos

Isolation of Adipose Tissue Immune Cells07:09

Isolation of Adipose Tissue Immune Cells

Published on: May 22, 2013

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice06:16

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview